Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Wang, Fanwen ^a   Yu, Tingting ^b   Zheng, Heng ^a   Lao, Xingzhen ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Dongyangguang pharmaceutical r d co LTD   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FUSION PROTEIN; HYDROCORTISONE; IMMUNOGLOBULIN FC FRAGMENT; THYMOSIN ALPHA1; TUMOR MARKER;

ANIMAL; BLOOD; BREAST TUMOR; DISEASE EXACERBATION; DISEASE MODEL; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL MELANOMA; FEMALE; GENETICS; HALF LIFE TIME; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; IMMUNOMODULATION; MALE; MELANOMA; METABOLISM; MOUSE; PATHOLOGY; PROGNOSIS; RAT;

ANIMALS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FEMALE; HALF-LIFE; HUMANS; HYDROCORTISONE; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOMODULATION; MALE; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; PROGNOSIS; RATS; RECOMBINANT FUSION PROTEINS; THYMALFASIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85051714656     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-30956-y     Document Type: Article

References (46)

1. Goldstein, A. L. et al. Purification and biological activity of thymosin, a hormone of the thymus gland. Proc Natl Acad Sci USA 69, 1800–3 (1972)
2. Romani, L. et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood. 103, 4232–9 (2004)
3. Wolf, G. T. et al. Interleukin 2 receptor expression in patients with head and neck squamous carcinoma. Effects of thymosin alpha 1 in vitro. Arch Otolaryngol Head Neck Surg. 115, 1345–9 (1989)
4. Baumann, C. A., Badamchian, M. & Goldstein, A. L. Thymosin alpha1 is a time and dose-dependent antagonist of dexamethasone-induced apoptosis of murine thymocytes in vitro. Int J Immunopharmacol. 22, 1057–66 (2000)
5. Goldstein, A. L. & Badamchian, M. Thymosins: chemistry and biological properties in health and disease. Expert Opin Biol Ther. 4, 559–73 (2004)
6. Liang, Y. R. et al. Thymosin alpha1 therapy subsequent to radical hepatectomy in patients with hepatitis B virus-associated hepatocellular carcinoma: A retrospective controlled study. Oncol Lett. 12, 3513-3518 (2016)
7. Wu, X., Jia, J. & You, H. Thymosin alpha-1 treatment in chronic hepatitis B. Expert Opin Biol Ther. 15(Suppl 1), S129–32 (2015)
8. Ciancio, A. et al. Thymosin alpha-1 with peginterferon alfa-2a/ribavirin for chronic hepatitis C not responsive to IFN/ribavirin: an adjuvant role? J Viral Hepat. 19(Suppl 1), 52–9 (2012)
9. Romani, L. et al. Thymosin alpha1 represents a potential potent single-molecule-based therapy for cystic fibrosis. Nat Med. 23, 590–600 (2017)
10. Danielli, R. et al. Thymosin alpha1 in melanoma: from the clinical trial setting to the daily practice and beyond. Ann NY Acad Sci. 1270, 8–12 (2012)
11. Garaci, E. et al. Thymosin alpha1 and cancer: action on immune effector and tumor target cells. Ann NY Acad Sci. 1269, 26–33 (2012)
12. Umeda, Y. et al. Thymosin alpha 1 restores NK-cell activity and prevents tumor progression in mice immunosuppressed by cytostatics or X-rays. Cancer Immunol Immunother. 15, 78–83 (1983)
13. Matteucci, C. et al. Thymosin alpha 1 and HIV-1: recent advances and future perspectives. Future Microbiol. 12, 141–155 (2017)
14. Xiang, X. S. et al. Combination therapy with thymosin alpha1 and dexamethasone helps mice survive sepsis. Inflammation. 37, 402–16 (2014)
15. Rustgi, V. Combination therapy of thymalfasin (thymosin-alpha 1) and peginterferon alfa-2a in patients with chronic hepatitis C virus infection who are non-responders to standard treatment. J Gastroenterol Hepatol. 19, S76–8 (2004)
16. Rath, T. et al. Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics. Crit Rev Biotechnol. 35, 235–54 (2015)
17. Mimoto, F. et al. Fc Engineering to Improve the Function of Therapeutic Antibodies. Curr Pharm Biotechnol. 17, 1298–1314 (2016)
18. Kontermann, R. E. Strategies for extended serum half-life of protein therapeutics. Curr Opin Biotechnol. 22, 868–76 (2011)
19. Ghose, S., Hubbard, B. & Cramer, S. M. Evaluation and comparison of alternatives to Protein A chromatography Mimetic and hydrophobic charge induction chromatographic stationary phases. J Chromatogr A. 1122, 144–52 (2006)
20. Strohl, W. R. Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters. BioDrugs. 29, 215–39 (2015)
21. Gopal, G. J. & Kumar, A. Strategies for the production of recombinant protein in Escherichia coli. Protein J. 32, 419–25 (2013)
22. Kontermann, R. E. Half-life extended biotherapeutics. Expert Opin Biol Ther. 16, 903–15 (2016)
23. Gribaudo, G. et al. Gamma-interferon: physico-chemical and biological characteristics. G Batteriol Virol Immunol. 77, 86–93 (1984)
24. Setrerrahmane, S. & Xu, H. Tumor-related interleukins: old validated targets for new anti-cancer drug development. Mol Cancer. 16, 153 (2017)
25. Sennikov, S. V. et al. Modern strategies and capabilities for activation of the immune response against tumor cells. Tumour Biol. 39, 1010428317698380 (2017)
26. Romani, L. et al. Thymosinalpha1: an endogenous regulator of inflammation, immunity, and tolerance. Ann N Y Acad Sci. 1112, 326–38 (2007)
27. Mandaliti, W. et al. Thymosin alpha1 Interacts with Exposed Phosphatidylserine in Membrane Models and in Cells and Uses Serum Albumin as a Carrier. Biochemistry. 55, 1462–72 (2016)
28. Mandaliti, W. et al. Thymosin alpha1 Interacts with Hyaluronic Acid Electrostatically by Its Terminal Sequence LKEKK. Molecules. 22, 11 (2017)
29. Umpierrez, G. E. et al. The effects of LY2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: the EGO study. J. Diabetes Obes Metab. 13, 418–25 (2011)
30. Cynthia, W. T. & Robert, S. K. Thymosin Apha 1–A Peptide Immune Modulator with a Broad Range of Clinical Applications. Clin Exp Pharmacol. 3, 2161–1459 (2013)
31. Jevremovic, M. et al. Determination of thymosin alpha 1 with enzyme-immunoassay in colorectal cancer patients. Arch Oncol. 5, 193–194 (1997)
32. Pica, F. et al. Serum thymosin alpha 1 levels in patients with chronic inflammatory autoimmune diseases. J. Clin Exp Immunol. 186, 39–45 (2016)
33. Sherman, K. E. et al. Low thymosin alpha-1 concentrations in patients chronically infected with the hepatitis B virus. J. Viral Immunol. 4, 195–9 (1991)
34. Moody, T. W. et al. Thymosin alpha 1 down-regulates the growth of human non-small cell lung cancer cells in vitro and in vivo. Cancer Res. 53, 5214–8 (1993)
35. Ni, C. et al. Thymosin alpha1 enhanced cytotoxicity of iNKT cells against colon cancer via upregulating CD1d expression. Cancer Lett. 356, 579–88 (2015)
36. Guo, Y. et al. Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K/Akt/mTOR signaling pathway. Apoptosis. 20, 1109–21 (2015)
37. Lyman, M. A. et al. The fate of low affinity tumor-specific CD8+ T cells in tumor-bearing mice. J Immunol. 174, 2563–72 (2005)
38. Janssen, E. M. et al. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 421, 852–6 (2003)
39. Yu, S. et al. IL-12 induced the generation of IL-21- and IFN-gamma-co-expressing poly-functional CD4+ T cells from human naive CD4+ T cells. Cell Cycle. 14, 3362–72 (2015)
40. Huang, Y. et al. CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome. Oncotarget. 6, 17462–78 (2015)
41. Mahmoud, S. M. et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 29, 1949–55 (2011)
42. Peng, Y. et al. CD86 is an activation receptor for NK cell cytotoxicity against tumor cells. PLoS One. 8, e83913 (2013)
43. Agadjanyan, M. G. et al. CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo. J Immunol. 162, 3417–27 (1999)
44. Petty, K. J. Metal-chelate affinity chromatography. Curr Protoc Protein Sci. Chapter 9 Unit9, 4 (2001)
45. Lin, A. V. Indirect ELISA. Methods Mol Biol. 1318, 51–9 (2015)
46. Feldman, A. T. & Wolfe, D. Tissue processing and hematoxylin and eosin staining. Methods Mol Biol. 1180, 31–43 (2014)